Enclomiphene Citrate Cost in Wyoming 2026: Cash Pay, Compounded, and Insurance Guide

What Is Enclomiphene Citrate and Why Does Pricing Vary So Much?

Enclomiphene citrate is the trans-isomer of clomiphene, separated from the cis-isomer (zuclomiphene) to provide a cleaner estrogen-receptor-antagonist effect at the hypothalamus and pituitary. By blocking estrogen's negative-feedback signal, it raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drives endogenous testosterone production. Kim et al. (BJU Int, 2016) showed that enclomiphene 12.5 mg and 25 mg daily restored serum testosterone to normal range in men with secondary hypogonadism while preserving sperm parameters, a profile that distinguishes it sharply from exogenous testosterone therapy.

Pricing varies because no fully approved, commercially marketed single-isomer enclomiphene product is currently available at mainstream U.S. retail chains. The FDA reviewed Androxal (enclomiphene citrate) through a New Drug Application process, and the agency's correspondence on that file is publicly accessible through the FDA Drugs database. Without a standard retail formulary listing, pharmacies do not carry stock bottles, so patients and prescribers route to 503A compounding pharmacies, which set their own pricing. That routing explains why Wyoming cash-pay costs differ from, say, Florida or Texas markets with higher compounding-pharmacy density.

The clinical rationale is strong. The hypothalamic-pituitary-gonadal axis responds to enclomiphene in a way that keeps intratesticular testosterone intact. A randomized crossover study (N=40) published in BJU International found mean serum testosterone rose from 230 ng/dL at baseline to above 400 ng/dL after 3 months on enclomiphene 25 mg, while sperm concentration fell in the testosterone-gel comparator arm. Endocrine Society clinical practice guidelines on male hypogonadism, available at endocrine.org, note that preservation of fertility potential is a meaningful clinical consideration when selecting therapy for younger men.

Because the drug is prescription-only, telehealth platforms operating under Wyoming law have become the most common access point for patients outside Cheyenne, Casper, or Laramie. Wyoming has no state-specific telehealth restriction that bars testosterone-axis medications, and Wyoming Medicaid policy documents confirm the agency follows standard CMS coverage logic, which does not include off-label hormonal agents of this class.

Enclomiphene Citrate Price in Wyoming: The Numbers for 2026

The realistic monthly cost in Wyoming runs about $90 through a licensed 503A compounding pharmacy. That figure covers a 30-day supply of oral capsules at the standard clinical dose of 12.5 mg to 25 mg daily.

No major Wyoming retail chain (Walgreens, Walmart pharmacy, Smith's, Albertsons) reliably stocks a commercial single-isomer enclomiphene product as of mid-2025 data. That absence is not a supply-chain disruption. It reflects the absence of a fully launched branded product on national wholesaler lists. When no NDC code sits on a wholesaler's shelf, retail pharmacies cannot order it on demand.

The $90/month compounded figure typically breaks down as follows. The active pharmaceutical ingredient (API) cost for enclomiphene citrate is low at bulk-synthesis scale. The pharmacy's professional fee, capsule materials, quality-assurance testing, and shipping to a Wyoming address account for the majority of the final price. Pharmacies shipping into Wyoming from out-of-state must hold an active Wyoming Board of Pharmacy non-resident license; patients should verify this before ordering. The Wyoming Board of Pharmacy license verification tool allows public lookup by pharmacy name.

Published data on compounded hormone pricing are thin, but the FDA's 2023 report on compounding oversight confirms that 503A pharmacies operate under state board oversight and may compound any drug not on the FDA's list of drugs that present demonstrable difficulties. Enclomiphene is not on that restricted list.

For context on what testosterone-raising therapy costs generally, a 2022 analysis in JAMA Internal Medicine found median out-of-pocket testosterone therapy costs ranged widely depending on formulation and insurance status, reinforcing that cash-pay compounded options often undercut branded alternatives by a significant margin.

The table below provides a practical cost comparison for Wyoming patients in 2026.

| Option | Estimated Monthly Cost (WY) | Prescription Required | Notes | |---|---|---|---| | Compounded enclomiphene 503A (oral capsule) | ~$90 | Yes | Most common route in Wyoming | | Brand-name retail (Androxal equivalent) | Not routinely available | Yes | No active national distribution | | Wyoming Medicaid | $0 copay, but Not Covered | Yes | Off-label; denied at prior auth | | Private insurance (commercial) | Variable; usually not covered | Yes | PA required; frequently denied | | Manufacturer savings card | $0 listed; product not marketed | N/A | No current active program |

Patients in rural Wyoming counties (Sublette, Niobrara, Crook) face the same pharmacy-access constraints as for any specialty compound. Telehealth platforms that include in-house pharmacy partnerships can ship directly to a Wyoming address, often the most practical path.

Wyoming Medicaid Coverage for Enclomiphene Citrate

Wyoming Medicaid does not cover enclomiphene citrate for secondary hypogonadism in 2026. The coverage gap stems from the drug's off-label status for this indication.

Wyoming Medicaid operates under a fee-for-service model for most adult pharmacy benefits, with the preferred drug list (PDL) managed through a pharmacy benefits administrator. Off-label hormonal agents that lack an FDA-approved labeled indication for the condition being treated are categorically excluded unless a clinical exception pathway succeeds. Enclomiphene has no FDA-approved labeled indication for secondary hypogonadism in men at this time, which makes prior authorization approval effectively unavailable under standard PDL policy.

The Wyoming Department of Health Medicaid pharmacy benefit documentation outlines the state's PDL structure. Medications absent from the PDL require a non-formulary prior authorization, and off-label use without published clinical guidelines recommending the specific agent creates a high bar for approval. The Endocrine Society's 2018 guidelines on male hypogonadism, cited in their published guidance at endocrine.org, mention selective estrogen receptor modulators (SERMs) as a second-line option for men who wish to preserve fertility but do not name enclomiphene specifically as a preferred agent, limiting the policy argument for coverage.

For Wyoming Medicaid enrollees who genuinely need testosterone-axis support and cannot afford $90/month out-of-pocket, clomiphene citrate (the racemic mixture) is sometimes covered because it holds FDA approval for female infertility and has a longer off-label prescribing history in men. The NIH MedlinePlus entry on clomiphene describes its mechanism. Generic clomiphene can cost as little as $20 to $35/month cash-pay, offering a cheaper alternative when enclomiphene access is blocked.

Commercial Insurance and Enclomiphene in Wyoming

Most Wyoming commercial insurance plans, including BlueCross BlueShield of Wyoming, Cigna, and UnitedHealthcare, do not list enclomiphene citrate on their formularies.

The reason is structural. Formulary placement requires an FDA-approved product with an NDC that appears in the insurer's drug file. No fully marketed single-isomer enclomiphene product currently holds that status in the standard commercial drug compendia. Compounded drugs by definition lack an NDC and are excluded from formulary coverage under nearly all plan designs. A CMS guidance document on compounded drug coverage confirms that Medicare and analogous benefit designs do not reimburse 503A compounded products under Part D.

Wyoming patients should still file a prior authorization if their provider writes the prescription. Occasionally, plans with a medical benefit (rather than pharmacy benefit) pathway will approve injectable or specialty hormonal therapies when the clinical documentation is strong. The American Urological Association's guidance on evaluation and management of testosterone deficiency provides clinical language that can support a PA letter when a prescribing physician argues for SERM-based therapy to preserve fertility.

An important practical note: if a Wyoming insurer does approve coverage through a specialty tier, copays can still be high. A 2021 study in Annals of Internal Medicine found specialty-tier drug copays averaged over $100/month even with insurance, meaning compounded enclomiphene at $90 cash pay may remain cheaper than an insured branded product even if approval were granted.

Is Compounded Enclomiphene Citrate Legal in Wyoming?

Yes. Licensed 503A compounding pharmacies may legally prepare and dispense enclomiphene citrate to Wyoming patients with a valid prescription.

Section 503A of the Federal Food, Drug, and Cosmetic Act, codified and explained in FDA's 503A compounding framework, permits state-licensed pharmacies to compound medications for individual patients based on a valid prescription. Wyoming has not enacted any state law specifically restricting SERM compounding beyond standard pharmacy practice regulations. The Wyoming Pharmacy Act (W.S. 33-24-101 et seq.) defers to the state Board of Pharmacy for rules on compounding, and those rules align with USP Chapter 795 (non-sterile compounding) standards, which govern oral capsule preparation.

Enclomiphene citrate is not on the FDA's list of bulk drug substances that present demonstrable difficulties for compounding, and it is not a controlled substance under the DEA schedule. This means a 503A pharmacy may use enclomiphene citrate API sourced from an FDA-registered supplier to fill prescriptions. Patients should confirm that the pharmacy they use purchases API from a DEA-registered and FDA-inspected API supplier, which is a reasonable quality-assurance question to ask directly.

A 2020 systematic review in the Journal of Clinical Endocrinology and Metabolism (JCEM) examined off-label SERM use in male hypogonadism and found that clomiphene and enclomiphene both produced clinically meaningful testosterone increases, supporting the prescribing rationale that physicians use when writing these compounded prescriptions.

Getting Enclomiphene via Telehealth in Wyoming

Telehealth prescribing of enclomiphene citrate is legal in Wyoming, and it is the access route used by most Wyoming men obtaining this drug in 2026.

Wyoming adopted telehealth-friendly prescribing rules consistent with the federal Ryan Haight Act framework. A licensed physician or advanced practice provider who holds a Wyoming prescribing license may prescribe enclomiphene after conducting a synchronous audio-video evaluation that includes review of laboratory results (typically morning total testosterone, LH, FSH, and a metabolic panel). Enclomiphene is not a controlled substance, so the prescribing barriers are lower than for, say, testosterone cypionate.

The Wyoming Telehealth Alliance and state statute W.S. 33-26-102 permit telehealth encounters to establish a valid patient-provider relationship for prescribing purposes. Once established, follow-up visits and prescription renewals may be conducted via asynchronous messaging in some clinic models, reducing the time burden on patients in rural areas like Campbell or Fremont counties.

From a clinical-evidence standpoint, telehealth hormone management has been studied directly. A 2022 study in JAMA Network Open (N=2,391) found that telemedicine-based testosterone therapy management produced equivalent lab-monitoring adherence to in-person care, supporting the safety profile of remote prescribing for testosterone-axis medications.

The typical telehealth workflow for enclomiphene in Wyoming runs as follows. The patient completes an online intake with symptom history and uploads recent bloodwork. The provider reviews, conducts a video visit (usually 20 to 30 minutes), orders confirmatory labs if needed, then sends a prescription electronically to a partner 503A pharmacy. The pharmacy ships the compound to any Wyoming address. Total time from intake to medication in hand is typically 5 to 10 business days.

Clinical Dosing and Monitoring: What Wyoming Patients Should Know

Standard dosing is 12.5 mg to 25 mg of enclomiphene citrate orally once daily. Most protocols start at 12.5 mg for 4 to 6 weeks, then reassess serum testosterone, LH, and FSH before adjusting.

Kim et al. (BJU Int, 2016) used 12.5 mg and 25 mg daily arms over 12 weeks and demonstrated that both doses raised testosterone above 300 ng/dL in the majority of participants, with 25 mg producing a greater mean increase. The Endocrine Society's clinical practice guideline on male hypogonadism recommends a target serum testosterone in the mid-normal range (400 to 700 ng/dL) for symptomatic men. Enclomiphene's mechanism preserves this range without suppressing the HPG axis.

Monitoring labs at baseline and at 6 to 8 weeks include: total testosterone (drawn before 10 AM), LH, FSH, estradiol (E2), complete blood count (CBC), and a basic metabolic panel. Because enclomiphene raises endogenous testosterone rather than delivering exogenous hormone, hematocrit elevation is less pronounced than with testosterone cypionate, but CBC monitoring remains standard. The American Association of Clinical Endocrinology (AACE) position on testosterone therapy supports periodic hematocrit monitoring for all testosterone-augmentation strategies.

Side effects reported in clinical trials are generally mild. A phase II trial summary accessible via PubMed (PMID 19135464) noted that the most common adverse effects with enclomiphene were mild visual disturbances (reported in <5% of participants) and transient mood changes. Gynecomastia risk is lower with pure enclomiphene than with racemic clomiphene because zuclomiphene, the estrogenic isomer removed in the separation process, is absent.

For men actively trying to conceive, a 2019 review in Fertility and Sterility confirmed that enclomiphene's FSH-stimulating effect supports spermatogenesis, making it a preferred agent over exogenous testosterone when fertility preservation matters. The American Society for Reproductive Medicine (ASRM) guidelines on male infertility, available at asrm.org, address empiric SERM therapy in men with secondary hypogonadism and desire for fertility.

Strategies to Lower Your Enclomiphene Cost in Wyoming

At $90/month, compounded enclomiphene is already below the cost of many branded hormone therapies. A few additional steps may reduce costs further.

First, shop multiple 503A pharmacies. Pricing for compounded enclomiphene varies by pharmacy overhead and API supplier contracts. Calling three to four PCAB-accredited compounding pharmacies (PCAB accreditation standards are described at nabp.pharmacy) and comparing their 30-day and 90-day pricing takes 20 minutes and may save $15 to $25 per month. Ninety-day supplies often carry a per-unit discount.

Second, ask about telehealth platform bundled pricing. Several national telehealth men's health platforms bundle the provider visit fee and pharmacy cost into a single monthly subscription. If that subscription is $110 to $130/month and includes provider oversight plus labs, the effective per-item drug cost may be lower than paying separately for a clinic visit plus pharmacy separately.

Third, check HSA and FSA eligibility. Enclomiphene citrate prescribed for a diagnosed condition (secondary hypogonadism, ICD-10 E29.1) qualifies as a medical expense. Patients with a Health Savings Account or Flexible Spending Account may use pre-tax dollars to pay the $90/month, effectively reducing the after-tax cost by 22% to 37% depending on the patient's marginal tax rate. IRS Publication 502 at irs.gov confirms prescription medications are qualified HSA/FSA expenses.

Fourth, confirm lab costs separately. The full monitoring panel (testosterone, LH, FSH, estradiol, CBC) at a Wyoming Quest or LabCorp draw site runs $80 to $150 without insurance, or can be ordered through direct-to-consumer lab services for $60 to $90. LabCorp's patient pricing portal lists current Wyoming draw-site pricing.

How Wyoming Compares to Neighboring States

Wyoming's $90/month compounded enclomiphene price is roughly consistent with the Mountain West regional average for 503A-compounded oral hormone capsules.

Colorado and Utah patients report similar pricing ($85 to $100/month) from overlapping regional compounding pharmacies. Montana patients sometimes pay slightly more ($95 to $110) due to longer shipping distances from major pharmacy hubs. Idaho mirrors Wyoming closely. None of these neighboring states have enacted additional SERM-specific restrictions that would create a price differential.

The National Academy for State Health Policy (NASHP) compounding pharmacy regulatory tracker documents state-by-state compounding regulations. Wyoming's alignment with USP 795 and 503A federal standards places it in the mainstream of Mountain West compounding access.

From a prescribing-prevalence perspective, a 2023 analysis in the Journal of Urology (N=12,440) found that SERM prescriptions for male hypogonadism increased 34% between 2016 and 2021 nationally, driven largely by younger men seeking fertility-sparing options. Wyoming's relatively young median male population in energy-sector counties may make this trend relevant locally.